Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) shares gained ground Friday, as the company, a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, today announces it will be presenting data on the use of PCS12852 to treat gastroparesis patients at the annual Digestive Disease Week (DDW) conference held in Chicago’s McCormick Place from May 6-9.
PCS12852 is a Phase 2b-ready, very potent and very selective novel 5-HT4 agonist, for which the company is exploring partnerships and other options to advance the program.
The study, titled “PCS12852, A Novel 5-HT4 Agonist Improves GCSI Symptom Scores and Gastric Emptying in Gastroparesis Patients,” will be presented during the May 6th Research Forum Session, AGA Gastroparesis and Small Intestinal Dysmotility held from 2-3:30 PM CT. Sian Bigora, Pharm.D., Processa Pharmaceuticals’ Chief Development and Regulatory Officer, will present the Phase 2a results on the improvement in symptom scores and gastric emptying rate in gastroparesis patients treated with PCS12852.
CEO David Young commented, “We continue to see encouraging results with our drug development pipeline, and inclusion in the DDW conference as an oral presentation is important and continued validation for our
Regulatory Science approach. Since the FDA-approved gastroparesis drugs have severe safety limitations, the fact that PCS12852 is ready to move to a Phase 2b trial given the positive safety and efficacy results in our proof-of-concept gastroparesis trial is a significant milestone.”
PCSA shares added three cents, or 5.9%, to 59 cents.
